|
Originally published In Press as doi:10.1074/jbc.M202647200 on June 10, 2002
J. Biol. Chem., Vol. 277, Issue 33, 30271-30282, August 16, 2002
Sustained Production of H2O2
Activates Pro-matrix Metalloproteinase-2 through Receptor Tyrosine
Kinases/Phosphatidylinositol 3-Kinase/NF- B Pathway*
Sang-Oh
Yoon,
Soo-Jin
Park,
Sun Young
Yoon,
Chang-Hyun
Yun, and
An-Sik
Chung
From the Department of Biological Sciences, Korea Advanced
Institute of Science and Technology, Taejon 305-701, South Korea
Received for publication, March 19, 2002, and in revised form, May 29, 2002
 |
ABSTRACT |
A rate-limiting step of tumor cell metastasis is
matrix degradation by active matrix metalloproteinases (MMPs). It is
known that reactive oxygen species are involved in tumor metastasis. Sustained production of H2O2 by phenazine
methosulfate (PMS) induced activation of pro-MMP-2 through the
induction of membrane type 1-MMP (MT1-MMP) expression in HT1080 cells.
MMP-2, MMP-9, and tissue inhibitor of metalloproteinase-1 and -2 levels
were changed negligibly by PMS. A one time treatment with
H2O2 did not induce activation of MMPs. It was
also demonstrated that superoxide anions and hydroxyl radicals were not
related to PMS action. PMS-induced pro-MMP-2 activation was regulated
by the receptor tyrosine kinases, especially the receptors of
platelet-derived growth factor and vascular endothelial growth factor,
and downstream on the phosphatidylinositol 3-kinase/NF- B pathway but
not Ras, cAMP-dependent protein kinase, protein kinase C,
and mitogen-activated protein kinases. PMS did not induce pro-MMP-2
activation in T98G and NIH3T3 cells. This may be related to a low level
of MT1-MMP, indicating a threshold level of MT1-MMP is important for
pro-MMP-2 activation. Furthermore, PMS increased cell motility and
invasion but decreased cell-cell interaction. Cell-matrix interaction
was not affected by PMS.
 |
INTRODUCTION |
Metastasis is a major cause of death among cancer patients. The
metastasis of cancer cells requires several sequential steps, such as
changes in cell-ECM1
interaction, the disconnection of intercellular adhesions and separation of single cells from solid tumor tissue, a degradation of
ECM, the locomotion of tumor cells into the extracellular matrix, the
invasion of lymph and blood vessels, immunologic escape in the
circulation, adhesion to endothelial cells, extravasation from lymph
and blood vessels, proliferation of cells, and the induction of
angiogenesis (1).
The main groups of proteolytic enzymes involved in the tumor invasion
are matrix metalloproteinases (MMPs). The MMPs, a family of
zinc-dependent endopeptidases, are involved in tumor
invasion, metastasis, and angiogenesis in cancer (2, 3). MMPs are important enzymes for the proteolysis of extracellular matrix proteins
such as collagen, proteoglycan, elastin, laminin, and fibronectin (4).
MMPs are synthesized as preproenzymes, and most of them are secreted
from the cells as proenzymes. Among previously reported human MMPs,
MMP-2 (gelatinase A/Mr 72,000 type IV
collagenase) and MMP-9 (gelatinase B/Mr 92,000 type IV collagenase) are thought to be key enzymes for degrading type IV collagen, which is a major component of the basement membrane (3).
Both MMP-2 and MMP-9 are abundantly expressed in various malignant
tumors (5) and contribute to invasion and metastasis (6).
Pro-MMP-2 can be activated by several mechanisms dependent on
stimulators and cell types. Initially, pro-MMP-2 can be activated by
the action of highly expressed MT1-MMP and the adequate expression of
TIMP-2 (7-9). In this situation, the balance between MT1-MMP and
TIMP-2 is important. At low concentrations, TIMP-2 binds to the
catalytic site of some activated MT1-MMP molecules, generating receptors for pro-MMP-2, thereby promoting MMP-2 activation. In this
situation, MT1-MMP forms a homophilic complex through the hemopexin-like domain that acts as a mechanism to keep MT1-MMP molecules close together to facilitate pro-MMP-2 activation (10). At
high concentrations, TIMP-2 binds and inhibits any active MT1-MMP, thus
completely preventing MMP-2 activation. Next, the down-regulation of
TIMP-2 by type IV collagen without affecting MT1-MMP can lead to
pro-MMP-2 activation (11). In this case, pro-MMP-2 activation involved
neither a transcriptional modulation of MMP-2, MT1-MMP, or TIMP-2
expression nor any alteration of MT1-MMP protein synthesis or
processing. Finally, activation of pro-MMP-2 in fibroblast culture in a
type I collagen lattice was induced intracellularly and is associated
with Golgi-enriched intracellular membranes without the help of MT1-MMP
(12).
Reactive oxygen species (ROS) are involved in aging and many diseases
as follows: cancer, diabetes mellitus, atherosclerosis, neurological
degeneration, angiogenesis, and tumor invasion. However, there are few
reports on what kinds of ROS and how ROS affect tumor cell invasion. In
particular, the specific mechanism of transcriptional regulation of
MT1-MMP expression has not yet been understood. Here we report that
sustained exposure of H2O2, not a one time
exposure of H2O2, to cells increases pro-MMP-2
activation through the induction of MT1-MMP expression, and this
activation is mediated via a receptor tyrosine
kinases/PI3-kinase/NF- B activation. The sustained production of
H2O2 also increased cell motility and invasion
but decreased cell-cell interaction.
 |
EXPERIMENTAL PROCEDURES |
Cell Culture and Materials--
HT1080 (fibrosarcoma), T98G
(glioblastoma), and NIH3T3 (mouse fibroblast) were grown in DMEM
supplemented with 10 mM HEPES, 50 mg/liter gentamicin
(Invitrogen), and 10% heat-inactivated fetal bovine serum. Human
endothelial cells were grown in endothelial cell growth media
(Clonetics). Peroxynitrite, hydrogen peroxide, sodium nitroprusside
(SNP), Gö6976, indomethacin, SB203580, FPTI III, quinacrine,
PD98059, H7, PDTC, NF- B SN50, rapamycin, LY294002, AG1024, AG1295,
AG1478, SU1498, and SU5402 were purchased from Calbiochem. Anti-MT1-MMP
antibody, 4-aminophenylmercuric acetate, phenazine methosulfate (PMS),
paraquat, dihydroethidium, 2',7'-dichlorofluorescin diacetate
(DCFH-DA), diethyldithiocarbamic acid (DDC), and benzoic acid were
obtained from Sigma. Purified pro-MMP-2 protein and anti-MMP-2
antibodies were obtained from Chemicon. Anti-phosphotyrosine and
anti-PDGF receptor antibodies were obtained from Santa Cruz Biotechnology.
Zymography--
All experiments, including zymography, were
performed in the absence of serum. Enzymatic activities of MMP-2 and
MMP-9 were assayed by gelatin zymography (13). Samples were
electrophoresed on a gelatin containing 10% SDS-polyacrylamide gel.
After electrophoresis, the gel was washed twice with washing buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl, 2.5% Triton
X-100), followed by a brief rinsing in washing buffer without Triton
X-100. The gel was incubated with incubation buffer (50 mM
Tris-HCl, pH 7.5, 150 mM NaCl, 10 mM
CaCl2, 0.02% NaN3, 1 µM
ZnCl2) at 37 °C. After incubation, the gel was stained
and destained. In this gel, a clear zone of gelatin digestion appeared,
indicating the presence of MMP.
[3H]Thymidine Incorporation Assay--
Cell
proliferation assay was performed using [3H]thymidine
incorporation method. Cells were plated on 6 wells and incubated. At
70-80% confluency, cells were treated with various agents, and
12 h later, 1 µCi of [3H]thymidine (Amersham
Biosciences) was added to each well and incubated for 24 h. The
cells were then washed twice with PBS (137 mM NaCl, 2.7 mM KCl, 4.3 mM
Na2HPO4·7H2O, and 1.4 mM KH2PO4) and lysed with 0.4 M NaOH. The radioactivity incorporated in the cells was
measured with a liquid scintillation counter.
Western Blot Analysis--
Western blot analysis for MMP-2 and
phosphotyrosine protein was performed. For MMP-2, conditioned media
were collected and concentrated using Centricon (Millipore).
Phosphotyrosine proteins were identified using cell lysate. Briefly,
samples were resuspended in reducing 5× sample buffer (60 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, 0.1% bromphenol blue), boiled for 5 min, and electrophoresed by SDS-PAGE. Proteins were then transferred to
Hybond-ECL (Amersham Biosciences). Blots were then blocked with a TTBS
(25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) containing 1% bovine serum albumin and probed with primary antibodies and secondary antibodies coupled to peroxidase. Blots were
developed using the enhanced chemiluminescence system (Amersham Biosciences).
Cell Invasion and Motility Assays--
5 × 104 cells/chamber were used for each invasion assay.
The lower and upper parts of Transwell (Corning Glass) were coated with
10 µl of type I collagen (0.5 mg/ml) and 20 µl of 1:2 mixture of
Matrigel:DMEM, respectively. Cells were plated on the Matrigel-coated Transwell. The medium of the lower chambers also contained 0.1 mg/ml
bovine serum albumin. The inserts were incubated for 18 h at
37 °C. The cells that had invaded the lower surface of the membrane
were fixed with methanol and stained with hematoxylin and eosin. Random
fields were counted under a light microscope.
To determine the effect of the agents on cell motility, cells were
seeded into Transwell on membrane filters coated with 10 µl of type I
collagen (0.5 mg/ml) at the bottom of the membrane. Migration in the
absence or presence of agents was measured as described in the invasion
assay. In addition to this, cell motility was measured using a
wound-healing method. Briefly, cells were grown to near-confluency, and
a wound was created with the blunt end of a yellow tip. This was
documented through time-lapse photography.
MMP Activity Assay--
MMP activity was measured using MMP
substrate
(7-methoxycoumarin-4-acetyl-Pro-Leu-Gly-Leu- -(2,4-dinitrophenylamino)-Ala-Ala-Arg amide, Sigma). Briefly, media were mixed with substrate and incubated at 37 °C. Fluorescence was measured using a fluorometer with
excitation at 325 nm and emission at 395 nm.
Plasmids--
MT1-MMP promoter region ( 788 to +52) was
PCR-amplified and inserted upstream of the pGL3 luciferase basic vector
(Promega). NF- B reporter vectors were purchased from
CLONTECH. I B- vector was provided by Dr. V. Imbert (Faculte de Medecine, France).
Transient Transfection and Reporter Gene Assay--
HT1080 cells
were plated in 6 wells and incubated at 37 °C. At 70-80%
confluency, the cells were washed with DMEM and incubated with DMEM
without serum and antibiotics for 5 h. 2 µg of reporter vector
and 0.5 µg of -galactosidase vector were transfected using LipofectAMINE 2000 reagent (Invitrogen). After incubation, cells were
lysed, and luciferase activity was measured using a luminometer. -Galactosidase activity was measured using O-nitrophenyl
-galactopyranoside as a substrate.
Cell-Cell Adhesion Assay--
HT1080 cells were plated in 24 wells and incubated at 37 °C to 100% confluency. Other HT1080 cells
were radiolabeled with [3H]thymidine overnight and
trypsinized. Radiolabeled cells were resuspended in DMEM with 10%
fetal bovine serum and added to the unlabeled attached 100% confluent
24 wells. After 1-2 h of incubation, nonadherent cells were collected.
Then plates were rinsed with PBS, which was collected in the same
container. Following this procedure, bound cells were trypsinized
completely and collected in other containers. Radioactivity was
measured by a liquid scintillation counter, and the percentage of
adherent cells was calculated.
Cell-Matrix Adhesion Assay--
24-Well plates were coated with
10 µg/ml of type I collagen or type IV collagen. Nonspecific binding
was blocked by PBS containing 2% bovine serum albumin for 2 h at
room temperature. Cells were radiolabeled with
[3H]thymidine overnight and trypsinized. Cells were then
plated on coated culture plates and incubated for 30 min. Nonadherent and adherent cells were collected and counted. The percentage of
adherent cells was calculated as described in the cell-cell adhesion assay.
RNA Isolation and Northern Blot Analysis--
Total cellular RNA
was purified from cultured cells using TRIreagent (Molecular Research
Center). For Northern blot analysis, 15 µg of RNA were
electrophoresed on 1% agarose gels containing 37% formaldehyde and
transferred to Hybond-N membrane (Amersham Biosciences) by capillary
transfer. The membrane was fixed using an optimized UV cross-linking
procedure. Prehybridization and hybridization were performed at
68 °C in ExpressHyb hybridization solution
(CLONTECH). cDNA probes for MMPs, TIMPs, and
glyceraldehyde-3-phosphate dehydrogenase were labeled with
[32P]dCTP (3000 Ci/mmol, Amersham Biosciences) using a
random primer kit (Takara, Japan). The blot was then washed twice with
2× SSC (300 mM NaCl, 30 mM sodium citrate, pH
7.0) containing 0.05% SDS at 25 °C, and 0.1× SSC containing 0.1%
SDS at 55 °C in order, and autoradiographed at 70 °C.
Confocal Microscopy--
Cells were plated onto a Lab-Tek
chamber slide (Nunc). When cells reached 70-80% confluency, PMS was
treated. After incubation, cells were treated with DCFH-DA (5 µM) or dihydroethidium (5 µM) for the
detection of H2O2 and superoxide anion amount,
respectively. Cells were then wash with PBS and subjected to confocal
microscopy (Zeiss).
Cytochrome c Reduction--
Cytochrome c reduction
was used to assess the superoxide production by PMS. Cells were washed
once with sodium phosphate buffer (2.35 g/liter NaHPO4/7.61
g/liter Na2HPO4, pH 7.4) and incubated with
medium containing 1 g/liter glucose, 0.2 g/liter CaCl2,
4.54 g/liter NaCl, 0.37 g/liter KCl in sodium phosphate buffer with 20 µM cytochrome c at 37 °C. The absorbance of
the medium was read spectrophotometrically at 550 nm.
Flow Cytometric Assessment of
H2O2--
Flow cytometric analysis for the
measuring the amount of intracellular H2O2 was
performed. Briefly, cells were incubated with DCFH-DA (5 µM) for 30 min at 37 °C. Cells were washed with PBS and trypsinized. After washing with PBS, 10 µl of propidium iodide (2.5 mg/ml) was added, and the amount of H2O2
was measured by a flow cytometer.
 |
RESULTS |
The Effects of ROS on MMPs Expression in HT1080 Cells--
To find
the ROS effects on cell viability and pro-MMPs activation in HT1080
cells, various ROS were treated in the cells. Cell viability was tested
by a [3H]thymidine incorporation assay, and MMP
expression levels were identified by a gelatin zymography. Both
noncytotoxic and cytotoxic concentrations of
H2O2 (Fig.
1A), peroxynitrite (Fig.
1B), and SNP (nitric oxide production, Fig. 1C)
treatments did not induce pro-MMPs activation. But
H2O2 above 50 µM increased
pro-MMPs production (Fig. 1A), whereas peroxynitrite
decreased it in a dose-dependent manner (Fig.
1B). SNP did not induce much change in pro-MMPs level (Fig.
1C). We further tested the effect of a well known superoxide anion-generating agent, PMS, on cell proliferation and MMPs expression. Non-cytotoxic concentration of PMS induced pro-MMP-2 activation, but
not pro-MMP-9, whereas cytotoxic concentration of PMS decreased pro-MMP-2 and pro-MMP-9 expressions and did not induce pro-MMP-2 activation (Fig. 1D). To identify whether the activated MMP
was MMP-2, a Western blot analysis was performed using anti-MMP-2 antibody. Fig. 1E shows that PMS induces pro-MMP-2
activation. To find the direct effects of ROS on pro-MMP activation,
ROS and ROS generating agents were added to conditioned media, which
were preincubated with HT1080 cells for 2 days and then collected. Both
low and high concentrations of H2O2,
peroxynitrite, and SNP treatments did not affect pro-MMPs activation
(data not shown).

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 1.
Effects of ROS on HT1080 cell viability and
MMPs activities. Various concentrations of
H2O2 (A), peroxynitrite
(B), SNP (C), and PMS (D) were treated
to the HT1080 cells. 2 days after the treatment, conditioned media were
collected, and gelatin zymography analysis was performed. E,
purified commercial pro-MMP-2 and 1 mM
4-aminophenylmercuric acetate (APMA)-treated pro-MMP-2 were
used as control. HT1080 cells were incubated for 2 days in the absence
or presence of 2 µM PMS. Conditioned media were collected
and concentrated. MMP-2 was identified by Western blot analysis using
anti-MMP-2 antibody.
|
|
Treatment with Intracellular Superoxide Anion-generating Agents
Increase pro-MMP-2 Activation through H2O2
Generation--
Cells were incubated with PMS for various times. PMS
induced pro-MMP-2 activation about 48 h after treatment (Fig.
2A). Menadione and paraquat,
which produce intracellular superoxide anion like PMS, also induced
pro-MMP-2 activation but did not affect pro-MMP-9 expression and
activation (Fig. 2B). MMP-2 activity was also measured using
the substrate, and it was found that PMS-, menadione-, and paraquat-treated groups showed higher MMP-2 activity than the untreated
group (Fig. 2C). PMS produces superoxide anion in cells, and
this can be converted into H2O2, hydroxyl
radical, and H2O by enzymes or metals.

View larger version (53K):
[in this window]
[in a new window]
|
Fig. 2.
Effects of superoxide anion-generating agents
on MMPs activities. A, all HT1080 cells were incubated
for 60 h. During incubation, PMS was treated for the indicated
times. After incubation, conditioned media were collected, and gelatin
zymography was performed. Con, control. B
and C, 5 µM menadione, 1 mM
paraquat, and 2 µM PMS were treated to the cells. 2 days
later, conditioned media were collected and gelatin zymography
(B) and MMPs activity analysis using MMPs substrate
(C) were performed. Data represent the mean ± S.D. of
three independent experiments. Results were statistically significant
(*, p < 0.01) using Student's t test.
D, HT1080 cells were treated with DDC. After 3 h, 2 µM PMS was added and incubated for 2 days. E,
benzoic acid, mannitol, Me2SO (DMSO), and
N-acetylcysteine (NAC) were pretreated for 3 h, and 2 µM PMS was added. After 2 days incubation,
zymography analysis was performed.
|
|
What kinds of ROS are involved in pro-MMP-2 activation? To determine
this, the cells were treated with DDC, a potent superoxide dismutase
inhibitor, which has been proven to increase superoxide anion but
decrease H2O2 (14-16). PMS did not induce
pro-MMP-2 activation in the presence of DDC (Fig. 2D), which
means that superoxide anion is not involved in pro-MMP-2 activation.
Further experiments were done using hydroxyl radical scavengers,
benzoic acid, mannitol, and Me2SO. Several times treatment
with these agents did not prevent pro-MMP-2 activation by PMS (Fig.
2E). The widely used antioxidant N-acetylcysteine
was effective in inhibiting pro-MMP-2 activation by PMS (Fig.
2E). These results suggest that H2O2
is responsible for pro-MMP-2 activation but not superoxide anion and
hydroxyl radical.
PMS Increases Superoxide Anion and H2O2 for
Long Periods--
Direct treatment with H2O2
did not induce pro-MMP-2 activation (Fig. 1A), but
intracellular H2O2 produced by PMS activated pro-MMP-2. To find the differences between the two sources,
intracellular and extracellular ROS levels were measured by several
methods. Dihydroethidium and DCFH-DA are specific dyes used for the
detection of superoxide anion and H2O2,
respectively. Direct treatment with H2O2 did
not last over 2 h (data not shown), whereas treatment with PMS
increased intracellular superoxide anion (Fig.
3A) and H2O2 (Fig. 3B) for 2 days after the
treatment, which was identified by a confocal microscopy. For the more
precise detection of intracellular superoxide anion and
H2O2, flow cytometry analysis was used. As shown in Fig. 3C, intracellular H2O2
increased time-dependently, and a similar result was
obtained in the case of intracellular superoxide anion, which was
measured by a flow cytometer using dihydroethidium (data not shown).
Extracellular superoxide anion production by PMS was measured using
cytochrome c reduction, and a high level of this anion was
present up to 2 days after treatment (Fig. 3D).

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 3.
Effects of PMS on ROS production. HT1080
cells were incubated for 48 h. During incubation, 2 µM PMS was treated for the indicated times. After
incubation, DCFH-DA (A) and dihydroethidium (B)
were added, and confocal microscopy analysis was performed.
Con, control. C, the same method was used
with A except flow cytometric analysis was used instead of
confocal microscopy. D, cells were incubated for 48 h.
During incubation 2 µM PMS was treated for the indicated
times. After incubation, media were used for cytochrome c
reduction assays.
|
|
The Sustained Production of H2O2 Induces
Pro-MMP-2 Activation through Increased MT1-MMP Expression without
Affecting Expressions of MMP-2 and TIMP-2--
To discover what kinds
of changes by PMS induced pro-MMP-2 activation, mRNA levels of MMPs
and TIMPs were investigated. As shown in Fig.
4, PMS increased MT1-MMP mRNA. This
increased level was continued 60 h after treatment, demonstrating
that the sustained production of H2O2
stimulates continuous induction of MT1-MMP but does not affect MMP-2,
MMP-9, TIMP-1, and TIMP-2 levels significantly.

View larger version (60K):
[in this window]
[in a new window]
|
Fig. 4.
Effects of PMS on transcriptional levels of
MMPs and TIMPs. HT1080 cells were treated with 2 µM
PMS for the indicated times, and RNA was extracted. Northern blot
analysis was carried out. RNA loading was normalized using the signal
obtained with a glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
|
|
PMS Induces Pro-MMP-2 Activation through the
PI3-K-dependent Pathway--
To find the mechanisms for
pro-MMP-2 activation by PMS, various inhibitors of cell signal
molecules were used. Appropriate concentrations of inhibitors were
determined, and it was found that inhibitors themselves did not affect
pro-MMP-2 activation (data not shown). Gö6976
(calcium-dependent protein kinase C inhibitor),
indomethacin (phospholipase A2 inhibitor, cyclooxygenase inhibitor), SB203580 (p38 inhibitor), FPTI III (Ras processing inhibitor), quinacrine (Mepacrine, phospholipase
A2 inhibitor), PD98059 (mitogen-activated protein
kinase/extracellular signal-regulated kinase kinase-extracellular
signal-regulated kinase (MEK-ERK) pathway inhibitor), and H7 (broad
serine/threonine kinase inhibitor, protein kinase A inhibitor, protein
kinase C inhibitor, and protein kinase G inhibitor) did not have any
inhibitory effect on pro-MMP-2 activation by PMS (Fig.
5A). These inhibitors were
treated twice during incubation, and similar results were obtained
(data not shown). Further experiments were performed using LY294002 (a
PI3-kinase inhibitor) and rapamycin (a Akt/mTOR-p70S6K
inhibitor). Treatment with LY294002 blocked pro-MMP-2 activation, whereas rapamycin did not show any effect (Fig. 5B). Because
PMS-induced pro-MMP-2 activation is processed by MT1-MMP induction, a
further experiment was done using a MT1-MMP promoter containing
reporter vectors. Wild type p85 (PI3-K subunit) overexpression
increased MT1-MMP promoter activity, whereas kinase-dead p85
overexpression decreased the promoter activity (Fig.
5C).

View larger version (39K):
[in this window]
[in a new window]
|
Fig. 5.
Involvement of PI3-K on PMS-induced pro-MMP-2
activation. A and B, various inhibitors were
pretreated to HT1080 cells for 3 h, and 2 µM PMS was
treated. 2 days after treatment, conditioned media were collected, and
zymography was performed. C, wild type or kinase-dead
(KD) PI3-K subunit p85 expression vectors were cotransfected
with MT1-MMP promoter containing reporter vectors. After 36 h of
incubation, luciferase activity was measured. Data represent the
mean ± S.D. of three independent experiments. Results were
statistically significant (*, p < 0.01) using
Student's t test. Con, control.
|
|
PMS Induces Pro-MMP-2 Activation via Receptor Tyrosine
Kinase-dependent Pathways--
Genistein (a tyrosine
kinase inhibitor) inhibited pro-MMP-2 activation as well as pro-MMP-2
expression, whereas treatment with both vanadate (a protein tyrosine
phosphatase inhibitor) and PMS led to increased activation of pro-MMP-2
to 62 kDa and a further 43 kDa (Fig.
6A). These results suggest
that the protein tyrosine kinase pathway plays a major role in
pro-MMP-2 activation by the sustained production of
H2O2. To confirm the inhibitory role of
genistein in pro-MMP-2 activation, a Northern blot analysis was
performed. Genistein decreased transcription levels of MT1-MMP as well
as MMP-2 but did not significantly alter the TIMP-2 level (Fig.
6B). To find which tyrosine kinase was involved in
PMS-induced pro-MMP-2 activation, total cell extracts were
electrophoresed, and Western blotting was performed using a
phosphotyrosine-specific antibody. As shown in Fig. 6C, the
amount of high molecular weight phosphotyrosine proteins increased with
time, but the low molecular weight phosphotyrosine proteins decreased
or did not change.

View larger version (52K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of tyrosine kinases on PMS-induced
pro-MMP-2 activation. A, genistein and vanadate were
pretreated to HT1080 cells for 3 h, and 2 µM PMS was
treated. 2 days after treatment, conditioned media were collected, and
zymography was performed. B, HT1080 cells were treated with
5 µM genistein. After 3 h, PMS were treated for
36 h, and Northern blot analysis was performed. C, 2 µM PMS was treated and incubated for the indicated times.
Western blot analysis was performed using phosphotyrosine-specific
antibody. Con, control. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
|
|
PMS Increases MT1-MMP Expression through PDGF Receptor--
High
molecular weight tyrosine kinases are generally receptor tyrosine
kinases, so that various receptor kinases inhibitors were treated
before PMS treatment. As shown in Fig.
7A, 0.5 µM AG1295 (a PDGF pathway inhibitor) inhibited pro-MMP-2 activation marginally, but 1 and 5 µM AG1295 inhibited it over
75-85%. SU1498 (a VEGF pathway inhibitor) inhibited it about
20-30%, and 10 µM SU5402 (a fibroblast growth factor
pathway inhibitor) showed minimal inhibitory effect on pro-MMP-2
activation, but AG1024 (insulin-like growth factor -1 and insulin
pathway inhibitor) and AG1478 (an epidermal growth factor pathway
inhibitor) did not inhibit PMS-induced pro-MMP-2 activation. To confirm
the PDGF receptor-dependent activation of pro-MMP-2
activation by PMS, the amount of phosphorylated PDGF receptor was
measured. As shown in Fig. 7B, PMS increased PDGF receptor
phosphorylation. AG1295 also decreased MT1-MMP promoter activity
(Fig. 7C).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 7.
Effects of PDGF receptor activation on
PMS-induced pro-MMP-2 activation. A, various
concentrations of receptor tyrosine kinases inhibitors were pretreated
for 3 h, and 2 µM PMS was added. 2 days after
treatment, gelatin zymography was performed. B, 2 µM PMS was treated for the indicated times, and cells
were lysed. Cell lysate was mixed with anti-PDGF receptor- antibody
and immunoprecipitated (IP). Western blot (IB)
analysis was performed using phosphotyrosine-specific antibody
(Ab) and PDGF receptor- antibody. C, MT1-MMP
promoter containing reporter vector was transfected to HT1080 cells.
After 12 h, 5 µM AG1295 was treated for 3 h,
and 2 µM PMS was treated for 36 h. Luciferase
activity was measured using a luminometer. Data represent the mean ± S.D. of three independent experiments. Results were statistically
significant (*, p < 0.01) using Student's
t test. Con, control.
|
|
PMS Induces Pro-MMP-2 Activation through NF- B--
The receptor
tyrosine kinases/PI3-K pathway generally induces NF- B activation. To
conclude if this is the case in PMS-induced pro-MMP-2 activation,
NF- B inhibitors were used. PDTC (general inhibitor) and NF- B SN50
(specific inhibitor peptide) blocked PMS-induced pro-MMP-2 activation,
but NF- B SN50N (inactive control for SN50) was not effective (Fig.
8A). Further studies were
performed using NF- B subunit p65 vector and inhibitory unit
I B- vector. As shown in Fig. 8B, p65 vector
overexpression increased MT1-MMP promoter activity, whereas I B-
overexpression decreased the promoter activity. Furthermore, genistein
and AG1295 decreased NF- B activity induced by PMS (Fig.
8C).

View larger version (29K):
[in this window]
[in a new window]
|
Fig. 8.
Effects of NF- B on
PMS-induced pro-MMP-2 activation. A, inhibitors of
NF- B were pretreated for 3 h, and 2 µM PMS was
added. 2 days after treatment, gelatin zymography was carried out.
B, p65 NF- B and I B- expression vectors were
cotransfected with MT1-MMP reporter vector. After 36 h of
incubation, luciferase activity was measured. C, NF- B
reporter vector was transfected as described under "Experimental
Procedures." AG1295 and genistein were pretreated for 3 h. After
that 2 µM PMS was treated. After 36 h, luciferase
activity was measured using a luminometer. Data represent the mean ± S.D. of three independent experiments. Results were statistically
significant (*, p < 0.05) using Student's
t test. Con, control; PDTC,
pyrrolidinedithiocarbamate.
|
|
PMS Does Not Activate pro-MMP-2 in T98G and NIH3T3 Cells--
To
investigate whether PMS-induced pro-MMP-2 activation is universal to
other cells, T98G and NIH3T3, which produce pro-MMP-2, were treated
with PMS. PMS did not induce pro-MMP-2 activation in these cells (Fig.
9A). Three days of incubation
with PMS showed the same results (data not shown). Transcriptional
levels of MT1-MMP, MMP-2, and TIMP-2 were measured by Northern
blotting. T98G cells expressed MMP-2 more than HT1080 cells, and NIH3T3
cells produced comparable amounts of MMP-2 to that of the HT1080 cells
(Fig. 9B). Levels of TIMP-2 were similar among the three
cells. However, NIH3T3 and T98G cells showed a minimal expression of
MT1-MMP compared with HT1080. To prove whether these cells express or
do not express MT1-MMP, a blotted membrane was exposed for several
days, and the MT1-MMP band was detected (data not shown), indicating
that these cells express very low amounts of MT1-MMP. NIH3T3 cells were
then treated with PMS, and the mRNA level of MT1-MMP was measured
by Northern blotting. Although it required a very long exposure time
for the detection of the low amount of MT1-MMP expression, the MT1-MMP
level in NIH3T3 cells increased over time (Fig. 9C) like
HT1080 cells (Fig. 4). We further tested the pro-MMP-2 activation using
human endothelial cells that produce a large amount of MT1-MMP. PMS
induced pro-MMP-2 activation in endothelial cells (Fig.
9D).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 9.
Effects of PMS on various cells.
A, T98G and NIH3T3 cells were treated with the indicated
concentrations of PMS for 2 days, and zymography was performed.
B, NIH3T3, HT1080, and T98G cells were treated with 2 µM PMS for 36 h, and Northern blotting was
performed. C, NIH3T3 cells were treated with 2 µM PMS for the indicated times, and Northern blot
analysis was performed. D, human endothelial cells were
treated with 2 µM PMS for 2 days, and zymography analysis
was performed. GAPDH, glyceraldehyde-3-phosphate
dehydrogenase.
|
|
Effects of PMS on Cell-Cell Interaction, Cell-Matrix Interaction,
Motility, and in Vitro Invasion--
To find whether PMS affects
cell-cell interaction or not, PMS was pretreated or treated at the
assay time. HT1080 cells pretreated for 24 h with PMS showed a
decrease in the cell-cell interaction by 50%, but cells treated with
PMS during the processing time of the assay showed no change (Fig.
10A). PMS had no influence on cell-collagen interaction irrespective of preincubation (Fig. 10B). Treatment with PMS increased cell motility through
Transwell (Fig. 10C) and spreading onto plasticware (Fig.
10D). DDC inhibited the cell motility induced by PMS (Fig.
10, C and D). PMS also increased cell invasion,
which was inhibited by DDC, but treatment with various concentrations
of H2O2 did not affect cell invasion (Fig. 10E).

View larger version (33K):
[in this window]
[in a new window]
|
Fig. 10.
Effects of PMS on cell-cell
interaction, cell-matrix interaction, motility, and invasion.
A, HT1080 cells were incubated in the presence (white
bar) or absence (black bar) of 2 µM PMS
for 24 h. During incubation, cells were radiolabeled. Cell-cell
interaction assay was then performed. In the case of no PMS-pretreated
group, PMS was added during cell-cell interaction assay (black
bar). B, HT1080 cells were pretreated with 2 µM PMS for 24 h, and cell-matrix interaction assay
was performed. C, cells were treated with 500 µM DDC for 3 h, and 2 µM PMS was
added. After 12 h, cell motility assay was performed for 18 h
of incubation time. D, cells were preincubated with 500 µM DDC and treated with PMS for 12 h. The wound was
generated, and cell motility was monitored. E, the same
method used in C using Matrigel-coated Transwell. Data
represent the mean ± S.D. of three independent experiments.
Results were statistically significant (*, p < 0.05 and **, p < 0.01) using Student's t
test.
|
|
 |
DISCUSSION |
ROS are produced by a variety of sources, mitochondrial oxidative
phosphorylation, ionizing radiation exposures, cytokines, growth
factors, metabolism of exogenous compounds, and pathological metabolic
processes. These ROS are involved in many natural and pathological
processes, including aging, cancer, diabetes mellitus, atherosclerosis,
neurological degeneration, angiogenesis, and metastasis (17).
Metastasis requires several sequential steps as described earlier, and
a rate-limiting step is degradation of matrix by active MMP-2 and MMP-9
(2). Overproduction of the proenzyme was not sufficient for the
acquisition of an invasive phenotype as only activated MMPs can
degrade the matrix. However, there are few reports on specific
mechanisms of MMPs activation and transcriptional regulation of MT1-MMP
expression. Here we try to elucidate what kinds of ROS and how ROS
regulate pro-MMPs activation and MT1-MMP expression. To our knowledge,
this is the first described intercellular regulation of MT1-MMP by
ROS.
PMS and paraquat have been used as superoxide anion-producing agents
(14, 18-20). PMS increased pro-MMP-2 activation (Fig. 2), cell
motility, and the invasion of cancer cells (Fig. 10), but treatment
with H2O2, peroxynitrite, and SNP (nitric oxide production) did not have an influence on the activation of MMPs and the
tumor invasion. The produced superoxide anion turns into H2O2 by superoxide dismutase and is further
catalyzed to H2O by catalase and glutathione peroxidase or
hydroxyl radical by metal ions, such as iron. As shown in Fig. 2,
H2O2 is responsible for pro-MMP-2 activation,
raising an important question. Why did direct H2O2 treatment and PMS-induced
H2O2 show different results? As shown in Fig.
3, PMS increased intracellular and extracellular superoxide and
H2O2 even 48 h after treatment, but one
time treatment with H2O2 did not sustain
intracellular H2O2 over 2 h, which was assayed by a flow cytometric analysis using DCFH-DA (data not shown).
Regulation of MMP-9 expression is well established, but mechanistic
processes of MMP-2 and MT1-MMP expressions and activation of pro-MMP-2
by ROS are not well understood. MMP-9 expression is regulated by c-Jun
NH2-terminal kinase, p38, extracellular signal-regulated
kinase, protein kinase C, and Ras pathway, dependent on cell types (3).
It has been shown that noncytotoxic H2O2 acts
as an intracellular messenger and activates c-Jun
NH2-terminal kinase, p38, extracellular signal-regulated
kinase, cAMP-dependent protein kinase, protein kinase C,
Ras, tyrosine kinases, and various other kinds of signal molecules (21,
22). To find the exact mechanism for
H2O2-induced pro-MMP-2 activation, various
kinds of inhibitors were treated. In contrast to MMP-9 expression,
pro-MMP-2 activation by PMS was not affected by mitogen-activated
protein kinases, cAMP-dependent protein kinase, protein
kinase C, protein kinase G, Ras, and phospholipase A2 (Fig.
5A). However, genistein, a tyrosine kinase inhibitor,
inhibited pro-MMP-2 activation (Fig. 6A) through MT1-MMP
down-regulation (Fig. 6B), and specifically PDGF and VEGF
receptors, receptor tyrosine kinases, were involved in PMS action about
75-85 and 20-30%, respectively (Fig. 7A). In addition, a
protein tyrosine phosphatase inhibitor plus PMS increased more
pro-MMP-2 activation (Fig. 6A). Furthermore, it was found
that PI3-kinase (Fig. 5) and NF- B activations (Fig. 8) are also
involved in a signal pathway of pro-MMP-2 activation through induction
of MT1-MMP expression. It is well established that growth factors
induce PI3-K activation, and in turn NF- B activation (23),
especially PDGF activates NF- B through Ras and PI3-K (24, 25). In
our studies, the Ras inhibitor did not reduce pro-MMP-2 activation
(Fig. 5A). It is shown that HT1080 cells express PDGF and
the PDGF receptor (26). Therefore, these results demonstrate that the
PDGF/PI3-K/NF- B pathway plays a key role in pro-MMP-2 activation
through MT1-MMP induction by the sustained production of
H2O2. The tyrosine kinase pathway was also
critical for MMP-2 expression (Fig. 6B) as well as pro-MMP-2 activation.
There are several reports on relationships between ROS, protein
tyrosine kinase, and NF- B. It has been suggested that the stimulatory effect of ROS on tyrosine phosphorylation is due to the
kinase activation in addition to phosphatase inhibition (27), and ROS
also increase expression of the growth factors and the phosphorylation
of growth factor receptors, types of receptor tyrosine kinases (21).
The activation of receptor tyrosine kinases, such as VEGF receptor and
PDGF receptor, increases H2O2 via PI3-K has
been reported previously (28-30). Therefore, it can be explained that
the sustained production of H2O2 by PMS
activates PDGF, VEGF, PI3-K, and the NF- B pathways. In turn
PDGF/PI3-K and VEGF/PI3-K pathways increase
H2O2, which is a positive feedback loop,
consisting of H2O2, PDGF, VEGF, and PI3-K.
Pro-MMP-2 activation by ROS may depend on cell types. The sustained
production of H2O2 induced pro-MMP-2 activation
in HT1080 cells and human endothelial cells, but T98G and NIH3T3 cells
did not show any effect with the same treatment (Fig. 9A).
This indicates that different cells react differently to the same
stimulator. Cells having a large amount of MT1-MMP, even weak
stimulations, can lead to pro-MMP-2 activation. If cells have a small
amount of MT1-MMP such as NIH3T3 and T98G, even strong stimulators
cannot activate pro-MMP-2, even though the level of MMP-2 expression is
high, as in T98G (Fig. 9B). This implies a threshold of
MT1-MMP level for MMP-2 activation. MT1-MMP is overexpressed in certain types of malignant tumor cells (31). Therefore, these cells can readily
achieve the MT1-MMP threshold level and activate pro-MMP-2 and further
promote metastasis and angiogenesis. However, many cells do not have
large amounts of MT1-MMP; therefore, a transient increase in tyrosine
kinases activity does not increase MT1-MMP to the threshold level. Only
sustained stimulation of tyrosine kinases increases the potential of
threshold level of MT1-MMP. HT1080 cells produce a large amount of
MT1-MMP even without stimulator (Fig. 9B). This can be
explained by constitutively active Akt, downstream target of PI3-K, in
HT1080 (32). Further studies were performed on the relationship between
PI3-K pathway and MT1-MMP expression in various cells. MT1-MMP not only
participates in the processing of pro-MMP-2 but also digests various
ECM components in vitro, including collagen (33), thereby
profoundly stimulating tumor cell invasion. These data explain why ROS
such as H2O2 accelerate metastasis and angiogenesis.
Besides matrix degradation by active MMPs, the cell-cell adhesion,
cell-matrix adhesion, and cell motility are closely associated with
tumor cell invasion and metastasis (1, 34, 35). For cells to invade the
matrix, intercellular adhesions are weakened and tumor cells separate
from solid tumor tissue. Therefore, weakening of the cell-cell
interaction accelerates tumor cell invasion. In addition, cellular
survival and invasion are promoted by cell-matrix interaction via
integrins. PMS reduced cell-cell interaction (Fig. 10A) and
increased cell motility (Fig. 10, C and D) but
did not affect cell-collagen interaction (Fig. 10B). It has
been shown that superoxide anion treatment enhances cell motility (36), but our studies showed that sustained production of
H2O2 by PMS is responsible for the increased
motility and invasion, but not superoxide anion, because DDC treatment
in the presence of PMS prevented these phenomena (Fig. 10,
C-E).
This study may explain the destructive role of chronic inflammation on
tissue. Inflammatory reactions, particularly chronic ones, can be a
significant source of oxidative stress. Leukocytes such as activated
macrophages and neutrophils release a number of ROS including
H2O2 and superoxide anion that can damage the nearby cells, and furthermore, these ROS have the potential to change
normal cells to tumor cells. It has been estimated that approximately
one-third of the world's cancers are due to the effects of chronic
inflammation (37). In addition, inflammation is found during matrix
remodeling in many clinical situations, including wound healing and
tumor invasion, thereby increasing tumor cell metastasis, which is
still not well understood. Tumor cells produce large amounts of ROS
(38), and sublethal amounts of superoxide anion protect cells from
apoptosis (14). During inflammation, NF- B, which is known to be
involved in cell survival, invasion, metastasis, and angiogenesis, is
activated (39). From this combined information, it can be proposed that
the sustained production of H2O2 from chronic
inflammation increases tumor cell resistance against the defense system
of the body and invasion through 1) a decrease in cell-cell attachment,
2) an increase in matrix degradation by increasing the MT1-MMP
expression and activation of pro-MMP-2, and 3) an increase in cell
motility. In particular, the protein tyrosine kinase/PI3-K/NF- B
pathway may be most important for pro-MMP-2 activation through MT1-MMP induction by chronic inflammation-induced H2O2.
Antioxidants such as N-acetylcysteine and protein tyrosine
kinase inhibitors such as genistein can be good candidates for the
application of anti-metastatic drugs.
 |
ACKNOWLEDGEMENT |
We thank Dr. V. Imbert (Faculte de Medecine,
France) for the kind gift of the I B- vector.
 |
FOOTNOTES |
*
This work was supported by a grant of the Korea Health 21 R&D Project, Ministry of Health and Welfare, Republic of Korea
(02-PJ1-PG10-20801-0001).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Dept. of Biological
Sciences, Korea Advanced Institute of Science and Technology, Taejon
305-701, South Korea. Tel.: 82-42-869-2625; Fax: 82-42-869-2610; E-mail: aschung@mail.kaist.ac.kr.
Published, JBC Papers in Press, June 10, 2002, DOI 10.1074/jbc.M202647200
 |
ABBREVIATIONS |
The abbreviations used are:
ECM, extracellular
matrix;
DDC, diethyldithiocarbamic acid;
MMP, matrix metalloproteinase;
MT1-MMP, membrane-type 1-matrix metalloproteinase;
PDGF, platelet-derived growth factor;
PMS, phenazine methosulfate;
TIMP, tissue inhibitor of matrix metalloproteinase;
DMEM, Dulbecco's
modified Eagle's medium;
PI3-K, phosphatidylinositol 3-kinase;
PBS, phosphate-buffered saline;
DCFH-DA, 2',7'-dichlorofluorescin diacetate;
VEGF, vascular endothelial growth factor;
ROS, reactive oxygen species;
SNP, sodium nitroprusside.
 |
REFERENCES |
| 1.
|
Liotta, L. A.,
Steeg, P. S.,
and Stetler-Stevenson, W. G.
(1991)
Cell
64,
327-336[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Chang, C.,
and Werb, Z.
(2001)
Trends Cell Biol.
11,
S37-S43[Medline]
[Order article via Infotrieve]
|
| 3.
|
Westermarck, J.,
and Kahari, V. M.
(1999)
FASEB J.
13,
781-792[Abstract/Free Full Text]
|
| 4.
|
Johnson, L. L.,
Dyer, R.,
and Hupe, D. J.
(1998)
Curr. Opin. Chem. Biol.
2,
466-471[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Johnsen, M.,
Lund, L. R.,
Romer, J.,
Almholt, K.,
and Dano, K.
(1998)
Curr. Opin. Cell Biol.
10,
667-671[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Liabakk, N. B.,
Talbot, I.,
Smith, R. A.,
Wilkinson, K.,
and Balkwill, F.
(1996)
Cancer Res.
56,
190-196[Abstract/Free Full Text]
|
| 7.
|
Sato, H.,
Takino, T.,
Okada, Y.,
Cao, J.,
Shinagawa, A.,
Yamamoto, E.,
and Seiki, M.
(1994)
Nature
370,
61-65[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Sternlicht, M. D.,
and Werb, Z.
(2001)
Annu. Rev. Cell Dev. Biol.
17,
463-516[CrossRef][Medline]
[Order article via Infotrieve]
|
| 9.
|
Forget, M. A.,
Desrosiers, R. R.,
and Beliveau, R.
(1999)
Can. J. Physiol. Pharmacol.
77,
465-480[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Itoh, Y.,
Takamura, A.,
Ito, N.,
Maru, Y.,
Sato, H.,
Suenaga, N.,
Aoki, T.,
and Seiki, M.
(2001)
EMBO J.
20,
4782-4793[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Maquoi, E.,
Frankenne, F.,
Noel, A.,
Krell, H. W.,
Grams, F.,
and Foidart, J. M.
(2000)
Exp. Cell Res.
261,
348-359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Lee, A. Y.,
Akers, K. T.,
Collier, M., Li, L.,
Eisen, A. Z.,
and Seltzer, J. L.
(1997)
Proc. Natl. Acad. Sci. U. S. A.
94,
4424-4429[Abstract/Free Full Text]
|
| 13.
|
Herron, G. S.,
Banda, M. J.,
Clark, E. J.,
Gavrilovic, J.,
and Werb, Z.
(1986)
J. Biol. Chem.
261,
2814-2818[Abstract/Free Full Text]
|
| 14.
|
Clement, M. V.,
and Stamenkovic, I.
(1996)
EMBO J.
15,
216-225[Medline]
[Order article via Infotrieve]
|
| 15.
|
Siwik, D. A.,
Tzortzis, J. D.,
Pimental, D. R.,
Chang, D. L.,
Pagano, P. J.,
Singh, K.,
Sawyer, D. B.,
and Colucci, W. S.
(1999)
Circ. Res.
85,
147-153[Abstract/Free Full Text]
|
| 16.
|
Brenneisen, P.,
Briviba, K.,
Wlaschek, M.,
Wenk, J.,
and Scharffetter-Kochanek, K.
(1997)
Free Radic. Biol. Med.
22,
515-524[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Shackelford, R. E.,
Kaufmann, W. K.,
and Paules, R. S.
(2000)
Free Radic. Biol. Med.
28,
1387-1404[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Copin, J. C.,
Gasche, Y., Li, Y.,
and Chan, P. H.
(2001)
FASEB J.
15,
525-534[Abstract/Free Full Text]
|
| 19.
|
Gardner, P. R.,
Raineri, I.,
Epstein, L. B.,
and White, C. W.
(1995)
J. Biol. Chem.
270,
13399-13405[Abstract/Free Full Text]
|
| 20.
|
Marsh, J. P.,
and Mossman, B. T.
(1991)
Cancer Res.
51,
167-173[Abstract/Free Full Text]
|
| 21.
| Rhee, S. G., Bae, Y. S., Lee, S. R., and Kwon, J. (2000)
Sci. STKE
stke.sciencemag.org/cgi/content/full/sigtrans;2000/53/pe1
|
| 22.
|
Guyton, K. Z.,
Liu, Y.,
Gorospe, M., Xu, Q.,
and Holbrook, N. J.
(1996)
J. Biol. Chem.
271,
4138-4142[Abstract/Free Full Text]
|
| 23.
|
Karin, M.,
and Ben-Neriah, Y.
(2000)
Annu. Rev. Immunol.
18,
621-663[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Romashkova, J. A.,
and Makarov, S. S.
(1999)
Nature
401,
86-90[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Marumo, T.,
Schini-Kerth, V. B.,
Fisslthaler, B.,
and Busse, R.
(1997)
Circulation
96,
2361-2367[Abstract/Free Full Text]
|
| 26.
|
Gupta, S.,
Stuffrein, S.,
Plattner, R.,
Tencati, M.,
Gray, C.,
Whang, Y. E.,
and Stanbridge, E. J.
(2001)
Mol. Cell. Biol.
21,
5846-5856[Abstract/Free Full Text]
|
| 27.
|
Schieven, G. L.,
Kirihara, J. M.,
Myers, D. E.,
Ledbetter, J. A.,
and Uckun, F. M.
(1993)
Blood
82,
1212-1220[Abstract/Free Full Text]
|
| 28.
|
Colavitti, R.,
Pani, G.,
Bedogni, B.,
Anzevino, R.,
Borrello, S.,
Waltenberger, J.,
and Galeotti, T.
(2002)
J. Biol. Chem.
277,
3101-3108[Abstract/Free Full Text]
|
| 29.
|
Sundaresan, M., Yu, Z. X.,
Ferrans, V. J.,
Irani, K.,
and Finkel, T.
(1995)
Science
270,
296-299[Abstract/Free Full Text]
|
| 30.
|
Bae, Y. S.,
Sung, J. Y.,
Kim, O. S.,
Kim, Y. J.,
Hur, K. C.,
Kazlauskas, A.,
and Rhee, S. G.
(2000)
J. Biol. Chem.
275,
10527-10531[Abstract/Free Full Text]
|
| 31.
|
Yamamoto, M.,
Mohanam, S.,
Sawaya, R.,
Fuller, G. N.,
Seiki, M.,
Sato, H.,
Gokaslan, Z. L.,
Liotta, L. A.,
Nicolson, G. L.,
and Rao, J. S.
(1996)
Cancer Res.
56,
384-392[Abstract/Free Full Text]
|
| 32.
|
Yoon, S. O.,
Kim, M. M.,
Park, S. J.,
Kim, D.,
Chung, J.,
and Chung, A. S.
(2002)
FASEB J.
16,
111-113[Abstract/Free Full Text]
|
| 33.
|
Ohuchi, E.,
Imai, K.,
Fujii, Y.,
Sato, H.,
Seiki, M.,
and Okada, Y.
(1997)
J. Biol. Chem.
272,
2446-2451[Abstract/Free Full Text]
|
| 34.
|
Genda, T.,
Sakamoto, M.,
Ichida, T.,
Asakura, H.,
and Hirohashi, S.
(2000)
Lab. Invest.
80,
387-394[Medline]
[Order article via Infotrieve]
|
| 35.
|
Kaczarek, E.,
Zapf, S.,
Bouterfa, H.,
Tonn, J. C.,
Westphal, M.,
and Giese, A.
(1999)
Int. J. Dev. Neurosci.
17,
625-641[CrossRef][Medline]
[Order article via Infotrieve]
|
| 36.
|
Muramatsu, H.,
Kogawa, K.,
Tanaka, M.,
Okumura, K.,
Nishihori, Y.,
Koike, K.,
Kuga, T.,
and Niitsu, Y.
(1995)
Cancer Res.
55,
6210-6214[Abstract/Free Full Text]
|
| 37.
|
Klein, G.
(1987)
Science
238,
1539-1545[Abstract/Free Full Text]
|
| 38.
|
Szatrowski, T. P.,
and Nathan, C. F.
(1991)
Cancer Res.
51,
794-798[Abstract/Free Full Text]
|
| 39.
|
Janssen-Heininger, Y. M.,
Poynter, M. E.,
and Baeuerle, P. A.
(2000)
Free. Radic. Biol. Med.
28,
1317-1327[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Gianni, B. Bohl, S. A. Courtneidge, and G. M. Bokoch
The Involvement of the Tyrosine Kinase c-Src in the Regulation of Reactive Oxygen Species Generation Mediated by NADPH Oxidase-1
Mol. Biol. Cell,
July 1, 2008;
19(7):
2984 - 2994.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. G. Spinale
Myocardial Matrix Remodeling and the Matrix Metalloproteinases: Influence on Cardiac Form and Function
Physiol Rev,
October 1, 2007;
87(4):
1285 - 1342.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M. Miller, M. J. Nolan, J. Choi, T. Koga, X. Shen, B. Y. J. T. Yue, and P. A. Knepper
Lactate Treatment Causes NF-{kappa}B Activation and CD44 Shedding in Cultured Trabecular Meshwork Cells
Invest. Ophthalmol. Vis. Sci.,
April 1, 2007;
48(4):
1615 - 1621.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.-M. Park, A. Kim, J.-H. Oh, and A.-S. Chung
Methylseleninic acid inhibits PMA-stimulated pro-MMP-2 activation mediated by MT1-MMP expression and further tumor invasion through suppression of NF-{kappa}B activation
Carcinogenesis,
April 1, 2007;
28(4):
837 - 847.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Araya, S. Cambier, A. Morris, W. Finkbeiner, and S. L. Nishimura
Integrin-Mediated Transforming Growth Factor-{beta} Activation Regulates Homeostasis of the Pulmonary Epithelial-Mesenchymal Trophic Unit
Am. J. Pathol.,
August 1, 2006;
169(2):
405 - 415.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Okada, M. Kobayashi, H. Tanaka, T. Kobayashi, H. Tazawa, Y. Iuchi, K. Onuma, M. Hosokawa, M. C. Dinauer, and N. H. Hunt
The Role of Nicotinamide Adenine Dinucleotide Phosphate Oxidase-Derived Reactive Oxygen Species in the Acquisition of Metastatic Ability of Tumor Cells
Am. J. Pathol.,
July 1, 2006;
169(1):
294 - 302.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Khan, S. S. Rahim, C. S. Boddupalli, S. Ghousunnissa, S. Padma, N. Pathak, D. Thiagarajan, S. E. Hasnain, and S. Mukhopadhyay
Hydrogen peroxide inhibits IL-12 p40 induction in macrophages by inhibiting c-rel translocation to the nucleus through activation of calmodulin protein
Blood,
February 15, 2006;
107(4):
1513 - 1520.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Monhian, B. S. Jewett, S. R. Baker, and J. Varani
Matrix Metalloproteinase Expression in Normal Skin Associated With Basal Cell Carcinoma and in Distal Skin From the Same Patients
Arch Facial Plast Surg,
July 1, 2005;
7(4):
238 - 243.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Robbesyn, N. Auge, C. Vindis, A.-V. Cantero, R. Barbaras, A. Negre-Salvayre, and R. Salvayre
High-Density Lipoproteins Prevent the Oxidized Low-Density Lipoprotein-Induced Endothelial Growth Factor Receptor Activation and Subsequent Matrix Metalloproteinase-2 Upregulation
Arterioscler. Thromb. Vasc. Biol.,
June 1, 2005;
25(6):
1206 - 1212.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Zahradka, G. Harding, B. Litchie, S. Thomas, J. P. Werner, D. P. Wilson, and N. Yurkova
Activation of MMP-2 in response to vascular injury is mediated by phosphatidylinositol 3-kinase-dependent expression of MT1-MMP
Am J Physiol Heart Circ Physiol,
December 1, 2004;
287(6):
H2861 - H2870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J.L. Mehta, J. Chen, F. Yu, and D.Y. Li
Aspirin inhibits ox-LDL-mediated LOX-1 expression and metalloproteinase-1 in human coronary endothelial cells
Cardiovasc Res,
November 1, 2004;
64(2):
243 - 249.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Mori, M. Shibanuma, and K. Nose
Invasive Potential Induced under Long-Term Oxidative Stress in Mammary Epithelial Cells
Cancer Res.,
October 15, 2004;
64(20):
7464 - 7472.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. L. Schiffrin and R. M. Touyz
From bedside to bench to bedside: role of renin-angiotensin-aldosterone system in remodeling of resistance arteries in hypertension
Am J Physiol Heart Circ Physiol,
August 1, 2004;
287(2):
H435 - H446.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Lateef, M. J. Stevens, and J. Varani
All-trans-Retinoic Acid Suppresses Matrix Metalloproteinase Activity and Increases Collagen Synthesis in Diabetic Human Skin in Organ Culture
Am. J. Pathol.,
July 1, 2004;
165(1):
167 - 174.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. van Lent, K. C. Nabbe, P. Boross, A. B. Blom, J. Roth, A. Holthuysen, A. Sloetjes, S. Verbeek, and W. van den Berg
The Inhibitory Receptor Fc{gamma}RII Reduces Joint Inflammation and Destruction in Experimental Immune Complex-Mediated Arthritides Not Only by Inhibition of Fc{gamma}RI/III but Also by Efficient Clearance and Endocytosis of Immune Complexes
Am. J. Pathol.,
November 1, 2003;
163(5):
1839 - 1848.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. R. Hess, E. A. Seftor, R. E. B. Seftor, and M. J. C. Hendrix
Phosphoinositide 3-Kinase Regulates Membrane Type 1-Matrix Metalloproteinase (MMP) and MMP-2 Activity during Melanoma Cell Vasculogenic Mimicry
Cancer Res.,
August 15, 2003;
63(16):
4757 - 4762.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|